On May 15, 2023 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, reported its VP of Business Development, Dr. Sari Fishman, will participate in BioEquity Europe which takes place on May 14th – 16th, 2023 in Dublin, Ireland.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Fishman will conduct one-on-one meetings with potential strategic partners for Can-Fite’s advanced stage pipeline including pharma companies focused on oncology, dermatology, and liver diseases. To date, Can-Fite has monetized its portfolio through out-licensing and distribution deals in select territories.
"We believe Namodenoson’s new indication for the treatment of pancreatic cancer is generating interest from companies that are looking to augment their portfolio with novel solutions for this devastating disease. We look forward to productive meetings at BioEquity," stated Dr. Sari Fishman.
Can-Fite recently announced plans to initiate an open-label Phase 2 exploratory trial to assess the efficacy and safety of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy. Pre-clinical studies conducted on advanced pancreatic carcinoma patient cells showed Namodenoson had a significant anti-cancer effect.
Acumen Research estimates the global pancreatic cancer therapeutics market was valued at approximately $3.6 billion in 2021 and is projected to grow to approximately $6.6 billion by 2030.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase 2 trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.